Analysis of Reportable Segments
Allergan PLC operates in 3 segments: US Specialized Therapeutics; US General Medicine; and International.
Segment Profit Margin
Allergan PLC, profit margin by reportable segment
| Dec 31, 2019 | Dec 31, 2018 | Dec 31, 2017 | Dec 31, 2016 | Dec 31, 2015 | |
|---|---|---|---|---|---|
| US Specialized Therapeutics | 66.88% | 69.38% | 69.53% | 72.43% | 75.01% |
| US General Medicine | 64.12% | 64.68% | 63.68% | 62.18% | 65.14% |
| International | 52.97% | 54.13% | 54.42% | 54.06% | 53.02% |
Based on: 10-K (reporting date: 2019-12-31), 10-K (reporting date: 2018-12-31), 10-K (reporting date: 2017-12-31), 10-K (reporting date: 2016-12-31), 10-K (reporting date: 2015-12-31).
| Segment profitability ratio | Reportable segment | The company |
|---|---|---|
| Segment profit margin | US Specialized Therapeutics | US Specialized Therapeutics segment profit margin ratio deteriorated from 2017 to 2018 and from 2018 to 2019. |
| US General Medicine | US General Medicine segment profit margin ratio improved from 2017 to 2018 but then slightly deteriorated from 2018 to 2019 not reaching 2017 level. | |
| International | International segment profit margin ratio deteriorated from 2017 to 2018 and from 2018 to 2019. |
Segment Profit Margin: US Specialized Therapeutics
Allergan PLC; US Specialized Therapeutics; segment profit margin calculation
| Dec 31, 2019 | Dec 31, 2018 | Dec 31, 2017 | Dec 31, 2016 | Dec 31, 2015 | |
|---|---|---|---|---|---|
| Selected Financial Data (US$ in thousands) | |||||
| Segment contribution | 4,561,300) | 4,801,500) | 4,730,500) | 4,209,600) | 3,232,900) |
| Net revenues | 6,820,000) | 6,920,300) | 6,803,600) | 5,811,700) | 4,309,800) |
| Segment Profitability Ratio | |||||
| Segment profit margin1 | 66.88% | 69.38% | 69.53% | 72.43% | 75.01% |
Based on: 10-K (reporting date: 2019-12-31), 10-K (reporting date: 2018-12-31), 10-K (reporting date: 2017-12-31), 10-K (reporting date: 2016-12-31), 10-K (reporting date: 2015-12-31).
1 2019 Calculation
Segment profit margin = 100 × Segment contribution ÷ Net revenues
= 100 × 4,561,300 ÷ 6,820,000 = 66.88%
| Segment profitability ratio | Reportable segment | The company |
|---|---|---|
| Segment profit margin | US Specialized Therapeutics | US Specialized Therapeutics segment profit margin ratio deteriorated from 2017 to 2018 and from 2018 to 2019. |
Segment Profit Margin: US General Medicine
Allergan PLC; US General Medicine; segment profit margin calculation
| Dec 31, 2019 | Dec 31, 2018 | Dec 31, 2017 | Dec 31, 2016 | Dec 31, 2015 | |
|---|---|---|---|---|---|
| Selected Financial Data (US$ in thousands) | |||||
| Segment contribution | 3,741,200) | 3,442,800) | 3,690,900) | 3,683,500) | 4,128,900) |
| Net revenues | 5,834,900) | 5,322,900) | 5,796,200) | 5,923,900) | 6,338,400) |
| Segment Profitability Ratio | |||||
| Segment profit margin1 | 64.12% | 64.68% | 63.68% | 62.18% | 65.14% |
Based on: 10-K (reporting date: 2019-12-31), 10-K (reporting date: 2018-12-31), 10-K (reporting date: 2017-12-31), 10-K (reporting date: 2016-12-31), 10-K (reporting date: 2015-12-31).
1 2019 Calculation
Segment profit margin = 100 × Segment contribution ÷ Net revenues
= 100 × 3,741,200 ÷ 5,834,900 = 64.12%
| Segment profitability ratio | Reportable segment | The company |
|---|---|---|
| Segment profit margin | US General Medicine | US General Medicine segment profit margin ratio improved from 2017 to 2018 but then slightly deteriorated from 2018 to 2019 not reaching 2017 level. |
Segment Profit Margin: International
Allergan PLC; International; segment profit margin calculation
| Dec 31, 2019 | Dec 31, 2018 | Dec 31, 2017 | Dec 31, 2016 | Dec 31, 2015 | |
|---|---|---|---|---|---|
| Selected Financial Data (US$ in thousands) | |||||
| Segment contribution | 1,802,000) | 1,897,200) | 1,806,400) | 1,557,700) | 1,159,600) |
| Net revenues | 3,402,000) | 3,504,700) | 3,319,500) | 2,881,300) | 2,187,300) |
| Segment Profitability Ratio | |||||
| Segment profit margin1 | 52.97% | 54.13% | 54.42% | 54.06% | 53.02% |
Based on: 10-K (reporting date: 2019-12-31), 10-K (reporting date: 2018-12-31), 10-K (reporting date: 2017-12-31), 10-K (reporting date: 2016-12-31), 10-K (reporting date: 2015-12-31).
1 2019 Calculation
Segment profit margin = 100 × Segment contribution ÷ Net revenues
= 100 × 1,802,000 ÷ 3,402,000 = 52.97%
| Segment profitability ratio | Reportable segment | The company |
|---|---|---|
| Segment profit margin | International | International segment profit margin ratio deteriorated from 2017 to 2018 and from 2018 to 2019. |
Net revenues
Allergan PLC, net revenues by reportable segment
US$ in thousands
| Dec 31, 2019 | Dec 31, 2018 | Dec 31, 2017 | Dec 31, 2016 | Dec 31, 2015 | |
|---|---|---|---|---|---|
| US Specialized Therapeutics | 6,820,000) | 6,920,300) | 6,803,600) | 5,811,700) | 4,309,800) |
| US General Medicine | 5,834,900) | 5,322,900) | 5,796,200) | 5,923,900) | 6,338,400) |
| International | 3,402,000) | 3,504,700) | 3,319,500) | 2,881,300) | 2,187,300) |
| Total | 16,056,900) | 15,747,900) | 15,919,300) | 14,616,900) | 12,835,500) |
Based on: 10-K (reporting date: 2019-12-31), 10-K (reporting date: 2018-12-31), 10-K (reporting date: 2017-12-31), 10-K (reporting date: 2016-12-31), 10-K (reporting date: 2015-12-31).
Segment contribution
Allergan PLC, segment contribution by reportable segment
US$ in thousands
| Dec 31, 2019 | Dec 31, 2018 | Dec 31, 2017 | Dec 31, 2016 | Dec 31, 2015 | |
|---|---|---|---|---|---|
| US Specialized Therapeutics | 4,561,300) | 4,801,500) | 4,730,500) | 4,209,600) | 3,232,900) |
| US General Medicine | 3,741,200) | 3,442,800) | 3,690,900) | 3,683,500) | 4,128,900) |
| International | 1,802,000) | 1,897,200) | 1,806,400) | 1,557,700) | 1,159,600) |
| Total | 10,104,500) | 10,141,500) | 10,227,800) | 9,450,800) | 8,521,400) |
Based on: 10-K (reporting date: 2019-12-31), 10-K (reporting date: 2018-12-31), 10-K (reporting date: 2017-12-31), 10-K (reporting date: 2016-12-31), 10-K (reporting date: 2015-12-31).